Patient disposition
The study enrollment period was April 19, 2019–March 1, 2021 across 29 medical centers in Japan. Overall, 37 patients were enrolled and provided written informed consent; 30 patients met the eligibility criteria and were randomized to the invimestrocel group (N = 20) and standard group (N = 10). All 30 patients received treatment (Fig. Patient disposition in the ONE-BRIDGE study